1. Home
  2. ARGX vs VOD Comparison

ARGX vs VOD Comparison

Compare ARGX & VOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARGX
  • VOD
  • Stock Information
  • Founded
  • ARGX 2008
  • VOD 1984
  • Country
  • ARGX Netherlands
  • VOD United Kingdom
  • Employees
  • ARGX N/A
  • VOD N/A
  • Industry
  • ARGX Biotechnology: Biological Products (No Diagnostic Substances)
  • VOD Telecommunications Equipment
  • Sector
  • ARGX Health Care
  • VOD Telecommunications
  • Exchange
  • ARGX Nasdaq
  • VOD Nasdaq
  • Market Cap
  • ARGX 33.0B
  • VOD 26.1B
  • IPO Year
  • ARGX 2017
  • VOD 1988
  • Fundamental
  • Price
  • ARGX $559.34
  • VOD $10.83
  • Analyst Decision
  • ARGX Strong Buy
  • VOD Sell
  • Analyst Count
  • ARGX 17
  • VOD 1
  • Target Price
  • ARGX $730.07
  • VOD N/A
  • AVG Volume (30 Days)
  • ARGX 442.4K
  • VOD 12.5M
  • Earning Date
  • ARGX 07-24-2025
  • VOD 07-22-2025
  • Dividend Yield
  • ARGX N/A
  • VOD 4.18%
  • EPS Growth
  • ARGX N/A
  • VOD N/A
  • EPS
  • ARGX 15.94
  • VOD N/A
  • Revenue
  • ARGX $2,643,062,000.00
  • VOD $40,475,572,836.00
  • Revenue This Year
  • ARGX $61.64
  • VOD $7.49
  • Revenue Next Year
  • ARGX $32.00
  • VOD $0.08
  • P/E Ratio
  • ARGX $32.32
  • VOD N/A
  • Revenue Growth
  • ARGX 82.13
  • VOD 14.43
  • 52 Week Low
  • ARGX $457.42
  • VOD $8.00
  • 52 Week High
  • ARGX $678.21
  • VOD $11.03
  • Technical
  • Relative Strength Index (RSI)
  • ARGX 51.64
  • VOD 61.94
  • Support Level
  • ARGX $536.02
  • VOD $10.81
  • Resistance Level
  • ARGX $568.47
  • VOD $10.97
  • Average True Range (ATR)
  • ARGX 15.32
  • VOD 0.11
  • MACD
  • ARGX 2.26
  • VOD 0.02
  • Stochastic Oscillator
  • ARGX 81.53
  • VOD 79.38

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

About VOD Vodafone Group Plc

Vodafone operates mobile and fixed-line networks and businesses in more than 20 countries. Its largest market is Germany, where it is the second mobile operator after Deutsche Telekom and owns a cable network after acquiring Kabel Deutschland in 2013 and Liberty Global Germany in 2019. In the UK it acts as a mobile operator and is attempting a merger with CK Hutchison. In 2024 Vodafone divested its Spanish and Italian divisions, given their low returns on invested capital.

Share on Social Networks: